Skip to main content
AKTX
NASDAQ Life Sciences

ASCO 接受Akari的AKTX-101 ADC摘要，增强了KRAS突变肿瘤的潜力

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$5.65
Mkt Cap
$6.722M
52W Low
$3.25
52W High
$63.2
Market data snapshot near publication time

summarizeSummary

Akari Therapeutics宣布其领先的TROP2靶向抗体药物结合物（ADC），AKTX-101的摘要已被接受并将在美国临床肿瘤学会（ASCO）2026年年会上在线发表。这标志着该公司首次被ASCO接受，并为其新型RNA剪切调节载体平台提供了重要的外部验证，特别是强调了其在治疗KRAS突变肿瘤方面的潜力。对于一家小盘生物科技公司来说，这是一个物质性的积极发展，提高了AKTX-101的可信度和知名度，因为它将在2026年底/2027年初推进到第1期临床开发。投资者将在2026年5月21日等待完整的发表，以获取有关临床前数据的更多细节。

在该公告发布时，AKTX的交易价格为$5.65，交易所为NASDAQ，所属行业为Life Sciences，市值约为$672.2万。 52周交易区间为$3.25至$63.20。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed AKTX - Latest Insights

AKTX
Apr 27, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
7
Akari Secures Australian Patent for Core ADC Payload, Bolstering Global IP
Sentiment: Positive
View Wiseek Article
AKTX
Apr 21, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
ASCO Accepts Akari's AKTX-101 ADC Abstract, Bolstering Potential for KRAS Mutant Tumors
Sentiment: Positive
View Wiseek Article
AKTX
Apr 20, 2026, 8:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Akari's AKTX-101 Demonstrates Superior Preclinical Potency in Cancer, Eyes Phase 1 Study
Sentiment: Positive
View Wiseek Article
AKTX
Apr 06, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
8
Akari Therapeutics Partners with WuXi XDC, Accelerating Novel ADC Payload IND Filing to Late 2026
Sentiment: Positive
View Wiseek Article
AKTX
Mar 30, 2026, 5:45 PM EDT
Source: Wiseek News
Importance Score:
8
Akari Therapeutics Posts $17.3M Net Loss, Shifts R&D Focus to ADC Pipeline
Sentiment: Negative
View Wiseek Article
AKTX
Mar 17, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Akari Therapeutics Announces 1-for-40 Reverse ADS Split to Maintain Nasdaq Listing
Sentiment: Negative
View Wiseek Article
AKTX
Mar 04, 2026, 4:52 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Key Insider Dr. Ray Prudo Invests $906K in Warrants, Increasing Stake to 8.9%
Sentiment: Positive
View Wiseek Article
AKTX
Mar 04, 2026, 4:44 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
9
Major Insider Samir Patel Invests $688K in Akari Therapeutics Warrants, Boosting Stake to 10.4%
Sentiment: Positive
View Wiseek Article
AKTX
Mar 02, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
9
Shareholders Approve Warrants Enabling Nearly 100% Potential Dilution
Sentiment: Negative
View Wiseek Article
AKTX
Feb 03, 2026, 11:15 AM EST
Filing Type: DEF 14A
Importance Score:
9
Akari Therapeutics Schedules Shareholder Vote on Warrants Enabling Significant Dilution and Capital Raise
Sentiment: Neutral
View Wiseek Article